Altamira Therapeutics Ltd. – NASDAQ:CYTO
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Altamira Therapeutics Ltd. stock price monthly change
-77.10%
month
Altamira Therapeutics Ltd. stock price quarterly change
-77.10%
quarter
Altamira Therapeutics Ltd. stock price yearly change
-90.63%
year
Altamira Therapeutics Ltd. key metrics
Market Cap | 1.13M |
Enterprise value | N/A |
P/E | -0.04 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.02 |
PEG ratio | N/A |
EPS | -228.57 |
Revenue | N/A |
EBITDA | 2.02M |
Income | -15.83M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAltamira Therapeutics Ltd. stock price history
Altamira Therapeutics Ltd. stock forecast
Altamira Therapeutics Ltd. financial statements
| Sep 2022 | -458.69K | -9.61M | 2095.32% |
|---|---|---|---|
| Dec 2022 | 0 | -802.07K | |
| Mar 2023 | 52.73K | -2.71M | -5139.89% |
| Jun 2023 | 52.73K | -2.71M | -5139.89% |
| 2025 | 0 | -1.34M | |
|---|---|---|---|
| 2026 | 4.97M | -747.21K | -15.01% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 6203962 | 8.02M | 129.41% |
|---|---|---|---|
| Jun 2023 | 6203962 | 8.02M | 129.41% |
| Sep 2023 | 7694259 | 888.91K | 11.55% |
| Dec 2023 | 7694259 | 1.23M | 16.06% |
| Sep 2022 | -1.54M | -304.13K | 1.64M |
|---|---|---|---|
| Dec 2022 | -1.54M | -304.13K | 1.64M |
| Mar 2023 | -3.85M | 120 | 3.84M |
| Jun 2023 | -3.85M | 120 | 3.84M |
Altamira Therapeutics Ltd. alternative data
| Aug 2023 | 16 |
|---|---|
| Sep 2023 | 16 |
| Oct 2023 | 16 |
| Nov 2023 | 16 |
| Dec 2023 | 16 |
| Jan 2024 | 16 |
| Feb 2024 | 16 |
| Mar 2024 | 16 |
| Apr 2024 | 16 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
Altamira Therapeutics Ltd. other data
100.00%
0.00%
of CYTO is owned by hedge funds
4.65K
-2.46K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2023 10 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 12 Sep 2023 | Q2 2023 Earnings Call Transcript |
| Q4 2022 18 May 2023 | Q4 2022 Earnings Call Transcript |
| Q4 2021 12 Apr 2022 | Q4 2021 Earnings Call Transcript |
-
When is Altamira Therapeutics Ltd.'s next earnings date?
Unfortunately, Altamira Therapeutics Ltd.'s (CYTO) next earnings date is currently unknown.
-
Does Altamira Therapeutics Ltd. pay dividends?
No, Altamira Therapeutics Ltd. does not pay dividends.
-
How much money does Altamira Therapeutics Ltd. make?
Altamira Therapeutics Ltd. has a market capitalization of 1.13M.
-
What is Altamira Therapeutics Ltd.'s stock symbol?
Altamira Therapeutics Ltd. is traded on the NASDAQ under the ticker symbol "CYTO".
-
What is Altamira Therapeutics Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Altamira Therapeutics Ltd.?
Shares of Altamira Therapeutics Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Altamira Therapeutics Ltd. have?
As Jul 2024, Altamira Therapeutics Ltd. employs 10 workers, which is 38% less then previous quarter.
-
When Altamira Therapeutics Ltd. went public?
Altamira Therapeutics Ltd. is publicly traded company for more then 11 years since IPO on 6 Aug 2014.
-
What is Altamira Therapeutics Ltd.'s official website?
The official website for Altamira Therapeutics Ltd. is altamiratherapeutics.com.
-
How can i contact Altamira Therapeutics Ltd.?
Altamira Therapeutics Ltd. can be reached via phone at +44 12955950.
Altamira Therapeutics Ltd. company profile:
Altamira Therapeutics Ltd.
altamiratherapeutics.comExchange:
NASDAQ
Full time employees:
10
Industry:
Biotechnology
Sector:
Healthcare
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Clarendon House
Hamilton, HM 11
Hamilton, HM 11
CIK: 0001601936
ISIN: BMG0360L1349
CUSIP: G0360L100
